Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, December 5, 2023
[ Tue, Dec 05th 2023
] - WOPRAI
[ Tue, Dec 05th 2023
] - WOPRAI
[ Tue, Dec 05th 2023
] - WOPRAI
[ Tue, Dec 05th 2023
] - WOPRAI
[ Tue, Dec 05th 2023
] - WOPRAI
[ Tue, Dec 05th 2023
] - WOPRAI
[ Tue, Dec 05th 2023
] - WOPRAI
[ Tue, Dec 05th 2023
] - WOPRAI
[ Tue, Dec 05th 2023
] - WOPRAI
[ Tue, Dec 05th 2023
] - WOPRAI
[ Tue, Dec 05th 2023
] - WOPRAI
[ Tue, Dec 05th 2023
] - WOPRAI
[ Tue, Dec 05th 2023
] - WOPRAI
[ Tue, Dec 05th 2023
] - WOPRAI
Mon, December 4, 2023
[ Mon, Dec 04th 2023
] - WOPRAI
[ Mon, Dec 04th 2023
] - WOPRAI
[ Mon, Dec 04th 2023
] - WOPRAI
[ Mon, Dec 04th 2023
] - WOPRAI
[ Mon, Dec 04th 2023
] - WOPRAI
[ Mon, Dec 04th 2023
] - WOPRAI
[ Mon, Dec 04th 2023
] - WOPRAI
[ Mon, Dec 04th 2023
] - WOPRAI
[ Mon, Dec 04th 2023
] - WOPRAI
[ Mon, Dec 04th 2023
] - WOPRAI
[ Mon, Dec 04th 2023
] - WOPRAI
[ Mon, Dec 04th 2023
] - WOPRAI
[ Mon, Dec 04th 2023
] - WOPRAI
Jason Gerberry Initiated (ARWR) at Strong Buy and Held Target at $29 on, Dec 4th, 2023
Jason Gerberry of B of A Securities, Initiated "Arrowhead Pharmaceuticals, Inc." (ARWR) at Strong Buy and Held Target at $29 on, Dec 4th, 2023.
Jason has made no other calls on ARWR in the last 4 months.
There are 6 other peers that have a rating on ARWR. Out of the 6 peers that are also analyzing ARWR, 2 agree with Jason's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Michael Ulz of "Morgan Stanley" Maintained at Hold with Decreased Target to $37 on, Thursday, November 30th, 2023
- Shawn Egan of "Citigroup" Initiated at Hold and Held Target at $33 on, Tuesday, September 19th, 2023
These are the ratings of the 4 analyists that currently disagree with Jason
- Luca Issi of "RBC Capital" Reiterated at Buy and Held Target at $50 on, Thursday, November 30th, 2023
- Patrick Trucchio of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $90 on, Wednesday, August 9th, 2023
- Alethia Young of "Cantor Fitzgerald" Maintained at Buy with Decreased Target to $47 on, Tuesday, August 8th, 2023
- Keay Nakae of "Chardan Capital" Reiterated at Strong Buy and Held Target at $60 on, Tuesday, August 8th, 2023
